CoChat

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab

Open access
Iida, Mari, Brand, Toni M, Starr, Megan M, Li, Chunrong, Huppert, Evan J, Luthar, Neha, Pedersen, Mikkel W, Horak, Ivan D, Kragh, Michael, Wheeler, Deric L · 2013 · Neoplasia
Cited by 75

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been approved for head and neck and colorectal cancer treatment, but many patients treated with cetuximab don't respond or eventually acquire resistance. To determine how tumor cells acquire resistance to cetuximab, we previously developed a model of acquired resistance using the non-small cell lung cancer line NCI-H226. These cetuximab-resistant (Ctx(R)) cells exhibit increased steady-state EGFR expression secondary to alterations in EGFR trafficking and degradation and, further, retained dependence on EGFR signaling for enhanced growth potential. Here, we examined Sym004, a novel mixture of antibodies directed against distinct epitopes on the extracellular domain of EGFR, as an alternative therapy for Ctx(R) tumor cells. Sym004 treatment of Ctx(R) clones resulted in rapid EGFR degradation, followed by robust inhibition of cell proliferation and down-regulation of several mitogen-activated protein kinase pathways. To determine whether Sym004 could have therapeutic benefit in vivo, we established de novo Ctx(R) NCI-H226 mouse xenografts and subsequently treated Ctx(R) tumors with Sym004. Sym004 treatment of mice harboring Ctx(R) tumors resulted in growth delay compared to mice continued on cetuximab. Levels of total and phospho-EGFR were robustly decreased in Ctx(R) tumors treated with Sym004. Immunohistochemical analysis of these Sym004-treated xenograft tumors further demonstrated decreased expression of Ki67, and phospho-rpS6, as well as a modest increase in cleaved caspase-3. These results indicate that Sym004 may be an effective targeted therapy for Ctx(R) tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1593/neo.131584

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 75

Metadata

Authors
Iida, M., Brand, T. M., Starr, M. M., Li, C., Huppert, E. J., Luthar, N., Pedersen, M. W., Horak, I. D., Kragh, M., & Wheeler, D. L.
Venue
Neoplasia
Publisher
Elsevier BV
Published
2013-10
Volume
15
Issue
10
Pages
1196-1206
ISSN
1476-5586 (ISSN-L)
OpenAlex
W1932563524
Cited by
75
References
8
FWCI
4.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab. https://app.cochat.ai/papers/10.1593/neo.131584
The paper
Iida, M., Brand, T. M., Starr, M. M., Li, C., Huppert, E. J., Luthar, N., Pedersen, M. W., Horak, I. D., Kragh, M., & Wheeler, D. L. (2013). Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab. Neoplasia. https://doi.org/10.1593/neo.131584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.